Coinbase Stock Technical Analysis: Signals, Trends Before Q4 Report

Coinbase Global Inc (NASDAQ:COIN), will be reporting its fourth-quarter earnings on Feb. 15. Wall Street expects 2 cents in EPS and $823.85 million in revenues.

Coinbase Global Inc (NASDAQ:COIN), will be reporting its fourth-quarter earnings on Feb. 15. Wall Street expects 2 cents in EPS and $823.85 million in revenues.

The company is known for being one of the leading cryptocurrency exchanges in the world. It provides a user-friendly platform that allows individuals to buy, sell, and trade a variety of cryptocurrencies, including popular ones like Bitcoin (CRYPTO: ETH), and Litecoin (CRYPTO: LITE).

Coinbase Stock Technical Setup

The technical setup for Coinbase stock suggests a strongly bullish trend and positive momentum.

The share price is consistently above its 5, 20, and 50-day exponential moving averages, indicating robust buying pressure and favoring future bullish movements.

Additionally, the eight-day simple moving average, 20-day simple moving average, 50-day simple moving average, and 200-day simple moving average all suggest a “Buy” signal as the stock price ($160.38) exceeds these averages.

Similarly, the eight-day exponential moving average, 20-day exponential moving average, and 50-day exponential moving average all indicate a “Buy” signal.

However, it’s worth noting that the Moving Average Convergence Divergence (MACD) is -0.73, suggesting a “Sell” signal. The Relative Strength Index (RSI) is 72.81, indicating that Coinbase Global is currently overbought.

On the other hand, the Bollinger Bands ($25) and Bollinger Bands ($100) both suggest a “Buy” signal. Investors may want to consider these mixed signals and monitor the stock closely for potential shifts in momentum.

Also Read: Coinbase Q4 Earnings Preview: Analysts Estimates, Bitcoin ETF Impact, International Expansion And More

Ratings & Consensus Estimates: Consensus analyst ratings on Coinbase stock stand at a Buy currently with a price target of $98.56.

Price Action: Coinbase stock was trading at $160.38 at the close of trading day on Feb. 14.

Read Next: Why Coinbase Shares Are On A Tear Ahead Of Earnings

Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Ultomiris Recommended For NMOSD EU Approval

Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). If authorised, Ultomiris would be the first and only approved long-acting C5 complement inhibitor for the treatment of AQP4 Ab+ NMOSD in the EU.

AZN